BRPI0817804A2 - agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo. - Google Patents

agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo.

Info

Publication number
BRPI0817804A2
BRPI0817804A2 BRPI0817804A BRPI0817804A BRPI0817804A2 BR PI0817804 A2 BRPI0817804 A2 BR PI0817804A2 BR PI0817804 A BRPI0817804 A BR PI0817804A BR PI0817804 A BRPI0817804 A BR PI0817804A BR PI0817804 A2 BRPI0817804 A2 BR PI0817804A2
Authority
BR
Brazil
Prior art keywords
active ingredient
therapeutic agent
acid addition
addition salts
enhancing skin
Prior art date
Application number
BRPI0817804A
Other languages
English (en)
Inventor
Koichiro Takeshita
Masahiro Yamashita
Naoki Ando
Shinji Ona
Original Assignee
Torii Pharmaceutical Co Ltd
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torii Pharmaceutical Co Ltd, Toray Industries filed Critical Torii Pharmaceutical Co Ltd
Publication of BRPI0817804A2 publication Critical patent/BRPI0817804A2/pt
Publication of BRPI0817804A8 publication Critical patent/BRPI0817804A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
BRPI0817804A 2007-10-05 2008-10-03 Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo BRPI0817804A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007262015 2007-10-05
PCT/JP2008/068092 WO2009044883A1 (ja) 2007-10-05 2008-10-03 モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬

Publications (2)

Publication Number Publication Date
BRPI0817804A2 true BRPI0817804A2 (pt) 2016-10-11
BRPI0817804A8 BRPI0817804A8 (pt) 2017-04-18

Family

ID=40526303

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817804A BRPI0817804A8 (pt) 2007-10-05 2008-10-03 Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo

Country Status (14)

Country Link
US (1) US20100222309A1 (pt)
EP (1) EP2196206B8 (pt)
JP (1) JP5613417B2 (pt)
KR (1) KR101173509B1 (pt)
CN (1) CN101848714B (pt)
AU (1) AU2008308005B2 (pt)
BR (1) BRPI0817804A8 (pt)
CA (1) CA2702032C (pt)
ES (1) ES2748274T3 (pt)
MX (1) MX2010003660A (pt)
PL (1) PL2196206T3 (pt)
RU (1) RU2440117C1 (pt)
TW (1) TWI453020B (pt)
WO (1) WO2009044883A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362830B (es) * 2010-01-29 2019-02-14 Toray Industries Agente terapeutico o profilactico para enfermedades del tracto biliar.
WO2012054566A2 (en) * 2010-10-19 2012-04-26 Memorial Sloan-Kettering Cancer Center 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
ES2586655T3 (es) 2011-01-31 2016-10-18 Toray Industries, Inc. (-)-17-(ciclopropilmetil)-3,14beta-dihidroxi-4,5alfa-epoxi-6beta-[N-metil-trans-3-(3-furil)acrilamido]morfinano para su utilización en el tratamiento o prevención de la caquexia por cáncer
EP2931725B1 (en) 2012-12-14 2017-02-15 Purdue Pharma LP Nitrogen containing morphinan derivatives and the use thereof
CA2896202A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
WO2016176657A1 (en) 2015-04-30 2016-11-03 Memorial Sloan-Kettering Cancer Center Mitragynine analogs and uses thereof
CN105461727A (zh) * 2015-12-01 2016-04-06 吕涛 一种纳呋拉啡的精制方法
WO2018160500A1 (en) 2017-03-03 2018-09-07 Ring Inc. Solar-charging mounting bracket for audio/video recording and communication devices
HUE069820T2 (hu) 2018-03-08 2025-04-28 Victoria Link Ltd Nalfurafin alkalmazása demielinizációs betegségek kezelésére
TWI893157B (zh) * 2020-06-30 2025-08-11 日商東麗股份有限公司 具有嗎啡喃骨架之化合物或其藥理學上可容許之酸加成鹽的用途
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923875A (en) * 1989-07-10 1990-05-08 Baker Cummins Pharmaceuticals, Inc. Method for treatment of mast cell-mediated dermatologic disorders
JP2521853B2 (ja) 1990-07-25 1996-08-07 タカラベルモント株式会社 化粧料
US6323212B1 (en) 1992-01-23 2001-11-27 Toray Industries, Inc. Morphinan derivative and its pharmaceutical applications
EP0661283B1 (en) 1993-07-19 1998-10-21 Toray Industries, Inc. Brain cell protective
EP0663401B1 (en) * 1993-07-23 2000-06-07 Toray Industries, Inc. Morphinan derivative and medicinal use
JPH07187990A (ja) 1993-12-24 1995-07-25 Toshiko Yamamoto 化粧料
ATE359076T1 (de) * 1996-11-25 2007-05-15 Toray Industries Mittel gegen juckreiz
US5834480A (en) * 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
WO1999005146A1 (en) 1997-07-25 1999-02-04 Toray Industries, Inc. Hyponatremia remedies
JP4359711B2 (ja) 1997-09-02 2009-11-04 東レ株式会社 薬物依存症治療薬
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
DE60039444D1 (de) 1999-08-24 2008-08-21 Toray Industries Heilmittel für neuropathischen schmerz und versuchstier-modelle des neuropathischen schmerzes
CA2442423C (en) 2001-03-30 2009-11-03 Toray Industries, Inc. Therapeutic drug for psychoneurotic disorders
EP1402899A4 (en) 2001-05-08 2009-03-11 Toray Industries MEANS FOR THE TREATMENT OF SEPSIS
JP2004107209A (ja) 2002-09-13 2004-04-08 Nippon Oruganon Kk 掻痒治療薬
RU2221545C1 (ru) * 2002-11-13 2004-01-20 Открытое Акционерное Общество "Фаберлик" Косметическое средство, улучшающее физиологическое состояние кожных покровов
JP4499034B2 (ja) * 2003-02-19 2010-07-07 久光製薬株式会社 Ｎ−アリール又はｎ−ヘテロアリールピペラジン誘導体及びそれを含有する医薬
JP2004352714A (ja) 2003-05-08 2004-12-16 Kyorin Pharmaceut Co Ltd 新規な４−（２−フロイル）アミノピペリジン誘導体
JP4381157B2 (ja) 2004-02-03 2009-12-09 久光製薬株式会社 ２，２−ジフェニル−１−エタノン誘導体及びそれを含有する医薬
ATE456373T1 (de) * 2004-11-29 2010-02-15 Unilever Nv Orale zusammensetzung zur verbesserung der hauteigenschaften
PT1870413E (pt) * 2005-03-10 2013-10-01 Toray Industries Agente antiprurítico para o pruridro provocado pela esclerose múltipla
WO2007053194A2 (en) * 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction
RU2299724C1 (ru) * 2005-11-14 2007-05-27 Открытое Акционерное Общество "Фаберлик" Средство, улучшающее физиологическое состояние клеток кожи

Also Published As

Publication number Publication date
CA2702032A1 (en) 2009-04-09
AU2008308005A1 (en) 2009-04-09
TWI453020B (zh) 2014-09-21
MX2010003660A (es) 2010-08-10
ES2748274T3 (es) 2020-03-16
CN101848714B (zh) 2014-08-20
JPWO2009044883A1 (ja) 2011-02-10
BRPI0817804A8 (pt) 2017-04-18
EP2196206A4 (en) 2010-09-22
CA2702032C (en) 2013-04-02
WO2009044883A1 (ja) 2009-04-09
KR20100049683A (ko) 2010-05-12
PL2196206T3 (pl) 2020-02-28
EP2196206A1 (en) 2010-06-16
RU2440117C1 (ru) 2012-01-20
CN101848714A (zh) 2010-09-29
US20100222309A1 (en) 2010-09-02
EP2196206B8 (en) 2019-11-13
EP2196206B1 (en) 2019-07-17
TW200927116A (en) 2009-07-01
JP5613417B2 (ja) 2014-10-22
KR101173509B1 (ko) 2012-08-14
AU2008308005B2 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
FR19C1040I2 (fr) Administration par voie respiratoire de principes actifs
BRPI0907591A2 (pt) Compostos e composição farmacêutica como moduladores de atividade de gpr119, método in vitro para modulação da atividade de gpr119 e usos do referido composto, seus sais farmaceuticamente aceitáveis ou suas composições farmacêuticas.
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112013011968A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
BRPI1014390A2 (pt) composto de sal de amônio quaternário, composição medicinal, e, agente preventivo ou terapêutico
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI0811436A2 (pt) Composto, uso de um composto, composição farmacêutica, e, metódos para a terapia da dor em um animal de sangue quente, para a terapia da bexiga super ativa em um animal de sangue quente, e para preparar um composto.
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
UY30373A1 (es) Derivados de fenilalanina, procedimientos de preparacion y aplicaciones
EP2799543A4 (en) HUMANIZED ANTI-EPIREGULIN ANTIBODY AND CANCER THERAPY AGENTS WITH THESE ANTIBODY AS ACTIVE AGENT
BR112015003376A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BR112012000908A2 (pt) liberação de agentes ativos através da barreira hematoencefálica mediada por peptídeo em associação não covalente
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0910740A2 (pt) sistema terapêutico transdérmico para a administração de fentanila ou um análogo da mesma
PL2744474T3 (pl) Medyczna kompozycja do ochrony skóry z kombinacją składników czynnych poprawiającą barierę skóry
BR112012005629A2 (pt) sistema terapêutico transdérmico para administrar fentanila ou um análogo da mesma
PL2196206T3 (pl) Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
WO2012097264A3 (en) Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: TORAY INDUSTRIES, INC. (JP)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]